Choose Your Country or Region

Ganetespib (STA-9090)

Name: Ganetespib (STA-9090)
Brand: Selleck Chemicals
SKU: S1159
Rating: 5 (47 reviews)

Catalog No.S1159

For research use only.

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Selleck's Ganetespib (STA-9090) has been cited by 47 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Related Compound Libraries

Other HSP (HSP90) Products

Zelavespib (PU-H71)^New

Zelavespib (PU-H71, NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008^New

VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78 (HSPA5, Bip), respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.
Geldanamycin (NSC 122750)

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Download Inhibitor Catalog

HSP (HSP90) Signaling Pathway Map

Biological Activity

Description

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Targets

HSP90 ^[1]
(OSA 8 cells)

4 nM

In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. ^[1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. ^[1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. ^[2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. ^[3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.^[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. ^[4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

NCI-H1975	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHjuS3c4OiCq		MXPJR\|UxRThibl2=	MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNES2OlUoRjJ{MUS0OlY2RC:jPh?=
NCI-H1975	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2XCTlQ5KGh?		M{jIc2lEPTB;MU[gcm0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF2NE[2OUc,OjJzNES2OlU9N2F-
Calu-6	MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:wN3ZKSzVyPU[0JI5O	NYL6cYV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
Calu-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17DcGlEPTB;NUigcm0>	NVnmVVFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2122	M{\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTV\|IH7N	NHvI[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
A549	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELBW4ZKSzVyPUSzJI5O	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H358	NIT5TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXKTWM2OD1{OTDuUS=>	NIPhR5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1734	NFLOZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2izXGlEPTB;Mkigcm0>	M4\LTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H727	NFTPd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfuOY5KSzVyPUK4JI5O	M2CwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
COR-L23	M{C3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPhb25YUUN3ME2yNkBvVQ>?	M4\4SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H1792	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJyIH7N	NX7mWGNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2009	NYXISYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEftZm9KSzVyPUG5JI5O	NHjnZpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
SK-LU-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfDOoZKSzVyPUG4JI5O	NH\5doI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H2212	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjmdZBKSzVyPUG3JI5O	NHzQPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H441	NULX[2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF2IH7N	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H2030	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTF{IH7N	MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H23	NFjGVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLLNlBYUUN3ME2xNUBvVQ>?	NXjLcGpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
HOP-62	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fOemlEPTB;MUGgcm0>	NVHMOZBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
IA-LM	NE\jR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\4UW9HUUN3ME2xNEBvVQ>?	MnTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H460	NFG2O2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PYcWlEPTB;ODDuUS=>	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ\|MEGyNlQ5RC:jPh?=
H157	NEfLUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LERWlEPTB;NzDuUS=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H1355	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD1TWM2OD13IH7N	M2PYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
VCaP	NULudI42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[xdndKSzVyPUegcm0>	MkC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUKwNFQoRjJ\|MUWyNFA1RC:jPh?=
LNCaP	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRThibl2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF3MkCwOEc,OjNzNUKwNFQ9N2F-
Ramos-RA1	M4C4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofLTWM2OD15LkSgcm0>	NFvl[pk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
Karpas-299	NEC4SVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDVTZpKSzVyPUmuOkBvVQ>?	M1rST\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
Kasumi-1	MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jtNmlEPTB;NT64JI5O	NFHMS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
CCRF-CEM (2)	M2PKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzTcJhKSzVyPUeuNkBvVQ>?	M2LqbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
CCRF-CEM (1)	M{DjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnoTWM2OD1zMj61JI5O	Mm\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
MOLT-4	NWTVXFFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7RcXFKSzVyPUGwMlYhdk1?	M2rTfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
RS4;11	NX[wW49WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7UTWM2OD1zMz61JI5O	MlTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
COG-LL-317	NVvPcnlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jTdWlEPTB;ND60JI5O	M2PsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
NALM-6	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HlXWlEPTB;MUGuO{BvVQ>?	NF23fpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
CHLA-136	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTkU5NKSzVyPUKzMlIhdk1?	NUP0UYNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
CHLA-90	NUjjeGtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\4bWlEPTB;MkKuN{BvVQ>?	NFX1Wow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
NB-EBc1	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LSemlEPTB;MU[uPEBvVQ>?	M{fK[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
NB-1643	NF24NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX1WYFlUUN3ME23MlQhdk1?	M2TYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
SJ-GBM2	M1P6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M161VWlEPTB;MUKuPUBvVQ>?	NFr5Tpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
CHLA-258	M1H2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTZwNDDuUS=>	M{nJfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
CHLA-10	NHfnNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTVwNzDuUS=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
CHLA-9	M{i2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTRwNjDuUS=>	NFjKRmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
TC-71	NUK2SFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDYTVB6UUN3ME20MlUhdk1?	M2W2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CzO\|QyLz5{M{OwN\|c1OTxxYU6=
CHLA-266	NV7XZ\|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ5LkGgcm0>	NWjKUGdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN\|A{PzRzPD;hQi=>
BT-12	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTF2LkOgcm0>	NFH3eGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN\|c1OSd-MkOzNFM4PDF:L3G+
Rh30	NEH6W\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjYco9KSzVyPUWuOkBvVQ>?	MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
Rh18	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\ae5hNUUN3ME22MlIhdk1?	MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
Rh41	NXPteVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HTd2lEPTB;MUCuOEBvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN\|MEO3OFE9N2F-
RD	NFGxOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\TRlhKSzVyPUigcm0>	MnrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEO3OFEoRjJ\|M{CzO\|QyRC:jPh?=
K033	MlTWRZBweHSxc3nzJGF{e2G7	M4TCW\|ExOCCwTR?=	M4HlSVczKGh?		MYjzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{	NV7tWGo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
M23	MY\BdI9xfG:\|aYOgRZN{[Xl?	MmfBNVAxKG6P	NVrGTYliPzJiaB?=		NGLjcZR{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m\|	NYHqRpBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
K029	MYLBdI9xfG:\|aYOgRZN{[Xl?	M2\mU\|ExOCCwTR?=	NVr1O5lFPzJiaB?=		M3fGZ5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K028	M2DwUmFxd3C2b4Ppd{BCe3OjeR?=	MXmxNFAhdk1?	NHm3RYM4OiCq		M3fDeJNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN?	NF3mbHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K008	M1rQZWFxd3C2b4Ppd{BCe3OjeR?=	NXnoRXJLOTByIH7N	MVO3NkBp		M2PkT5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN?	NXPGT3NHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
K033	MoDFSpVv[3Srb36gRZN{[Xl?	MniwNlUxKG6P	MYKyOEBp		NETpfoJqdmS3Y3XzJIEhdW:mZYP0JIlv[3KnYYPlJIlvKEdzIIDvdJVt[XSrb36=	NUPvOVFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
M23	NYG1TJVWTnWwY4Tpc44hSXO\|YYm=	Moe0NlUxKG6P	NWm4W2FYOjRiaB?=		MljzbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K029	M3fINmZ2dmO2aX;uJGF{e2G7	NVLENIRKOjVyIH7N	MVKyOEBp		M{XuPIlv\HWlZYOgS\|Eh[XK{ZYP0	MnnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ\|NEG4OVI{RC:jPh?=
K028	M3rv[mZ2dmO2aX;uJGF{e2G7	M3fSNlI2OCCwTR?=	M3zWZlI1KGh?		M2POTIlv\HWlZYOgS\|Ih[XK{ZYP0	M4DQeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K008	MkjKSpVv[3Srb36gRZN{[Xl?	NEL0XlYzPTBibl2=	M3PBTVI1KGh?		M4jwSIlv\HWlZYOgS\|Ih[XK{ZYP0	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K033	M1S0ZWNmdGxiVnnhZoltcXS7IFHzd4F6				NXfRR2NMUUN3ME23OU42KG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
M23	NYfYVWl6S2WubDDWbYFjcWyrdImgRZN{[Xl?				MYnJR\|UxRTN5LkWgcm0>	M1jjd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K029	MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				MULJR\|UxRTR4IH7N	M{[1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K028	MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				NFTaRm1KSzVyPUi0JI5O	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K008	M2fPNWNmdGxiVnnhZoltcXS7IFHzd4F6				MoizTWM2OD14MDDuUS=>	NX\BfpRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ\|PD;hQi=>
H3122	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXqyfYQzOC1zMECwJI5O	NHnTNIM4OiCq		MYTJR\|UxRTFyIH7N	NV\NNoJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|MzPjVpPkKzOVM{OjZ3PD;hQi=>
H2228	NHrwTXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mn3ENE0yODByIH7N	M4HKWlczKGh?		NH3wW3ZKSzVyPUGzJI5O	NFHxNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzN\|I3PSd-MkO1N\|MzPjV:L3G+
A1847	NIjW[FNCeG:ydH;zbZMhSXO\|YYm=	MnHBNVAuOTByIH7N	MW[yOE81QC95MjDo		M3TWSolv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN\|Y9N2F-
OVCAR-8	NHO1RXdCeG:ydH;zbZMhSXO\|YYm=	MUWxNE0yODBibl2=	M{mxVVI1NzR6L{eyJIg>		MXTpcoR2[2W\|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN\|Y9N2F-
OVCAR-5	MlfYRZBweHSxc3nzJGF{e2G7	NGfwPZUyOC1zMECgcm0>	MorqNlQwPDhxN{KgbC=>		MWTpcoR2[2W\|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7	NUDDZXJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
SKOV-3	M1XzeGNmdGxiVnnhZoltcXS7IFHzd4F6	M1TCb\|AuOTByMDDuUS=>	MVe3NkBp		M4TmXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NF7hbo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
A1847	MoPER4VtdCCYaXHibYxqfHliQYPzZZk>	MkDtNE0yODByIH7N	NVziW4Z4PzJiaB?=		NF;NW5pqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN\|YoRjJ\|OUCwNVM3RC:jPh?=
OVCAR-8	MkXsR4VtdCCYaXHibYxqfHliQYPzZZk>	NFTHfpcxNTFyMECgcm0>	NED5SZM4OiCq		NEHsdolqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN\|Y9N2F-
OVCAR-5	M2fpemNmdGxiVnnhZoltcXS7IFHzd4F6	NVr5TpVbOC1zMECwJI5O	MUC3NkBp		NVO3cmVscW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NHjXWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
H146	NGXC[FlHfW6ldHnvckBCe3OjeR?=	M3XnfFMxKG6P	MYW3NkBp		NFLoNWpqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q>	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
GLC4	MV3GeY5kfGmxbjDBd5NigQ>?	NEXrdIE{OCCwTR?=	MYC3NkBp		M3rUSolv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	NX[wdZV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H82	M4TCW2Z2dmO2aX;uJGF{e2G7	MXGzNEBvVQ>?	NEDYNY04OiCq		MoPMbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0	M1;kOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
AC3	NHr1dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrWTWM2OD1{NT65JI5O	NWqwbnRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H1173	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7BTWM2OD1zMj62NkBvVQ>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H792	NFj4S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HrTmlEPTB;NEWuNFchdk1?	NWK5Z5FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H620	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXNTWM2OD1\|Mj62O{BvVQ>?	Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
N592	M2XFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrZemdXUUN3ME2xOE4yOiCwTR?=	NFKxNHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H526	NFnrZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvvTWM2OD1{MT62OEBvVQ>?	NIXsdIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H187	NEj6R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXSTWM2OD1{ND65PUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H146	NF;GR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIizXG9KSzVyPUK4MlUyKG6P	MnrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H128	NFG5WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzQTWM2OD14OT61OUBvVQ>?	M{nOeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H69	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jGTmlEPTB;OEOuN\|Yhdk1?	NI\0Uoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
GLC4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDVNopiUUN3ME2yNE41PyCwTR?=	NWfFcIZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H82	NXHGV29rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnhfZhtUUN3ME2zNE4zPyCwTR?=	MnTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
MDA-MB-231	MXvGeY5kfGmxbjDBd5NigQ>?	MV[xNFAhdk1?	M1;CfVI1KGh?		NWfTXotVcW6qaXLpeJMhfGinIH3p[5JifG:{eTDhcoQhcW64YYPpeoUh[2GyYXPpeJnDqA>?	MlPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{O1OFEoRjJ2MUezOVQyRC:jPh?=
BT-20	NWDjTYU5TnWwY4Tpc44hSXO\|YYm=	Mn\0NVAxNzJ3MDDuUS=>	M4W4OVI1KGh?		Mk\1doV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFH	NYDufpRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|M2PDFpPkK0NVc{PTRzPD;hQi=>
MDA-MB-435	NI[4N2dHfW6ldHnvckBCe3OjeR?=	NFTicWgyODBibl2=	MkHaN\|AhdWmw		M17YNolvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7z	MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
MDA-MB-231	MkPQSpVv[3Srb36gRZN{[Xl?	NXfNN2hCOTByIH7N	Mlv6N\|AhdWmw		NHHZdG1qdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?=	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
HCC2998	NYHwV29HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TR[GlEPTB;MUK4JI5O	MnLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
SK-CO-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRThzIH7N	M1;6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
LS-123	NVLEVpM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;lTWM2OD15MzDuUS=>	NIfj[YM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
SNU-C2B	NV6xXYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHKTWM2OD12NTDuUS=>	MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
LS-1034	MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HIN2lEPTB;M{Ggcm0>	M4r5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
LoVo	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW5TWM2OD1{MjDuUS=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
COLO-678	NUTwNVZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLBTWM2OD1{MTDuUS=>	NGPBNWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
NCI-H747	NHzx[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTF5IH7N	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
COLO-205	NGLPbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjvNoFKSzVyPUG0JI5O	M4j5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT 116	NYO1UZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTF2IH7N	M2Lr[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO\|Q4Lz5{NE[4Nlc1PzxxYU6=
HuTu-80	NEDPSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjhZWdZUUN3ME2xN{BvVQ>?	MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
HCT-15	MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRThibl2=	NG\XRYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
SW620	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LrdWlEPTB;ODDuUS=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
LS-411 N	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjqc\|FIUUN3ME21JI5O	Mo\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO\|Q4RC:jPh?=
RKO	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXH3V3N4UUN3ME20JI5O	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
SW780	M4C0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrOVm9KSzVyPUO0OVEhdk1?	NUHqPFdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
RT4	NEWx[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fYd2lEPTB;MUezN{BvVQ>?	NE\YXmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
TCCSUP	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M376TWlEPTB;MUSyJI5O	NX3G[Xp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
MGH-U3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHHTWM2OD13MzDuUS=>	NYXhe3lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
HT-1197	NFqyW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MornTWM2OD13MzDuUS=>	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
5637	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rzfGlEPTB;NESgcm0>	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
35612	M3;5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILTUG5KSzVyPUO4JI5O	Mlj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
KU-19-19	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTN4IH7N	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
LB831-BLC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTN2IH7N	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
UM-UC3	NFfrOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX[ycpVVUUN3ME2zN{BvVQ>?	NIW1TpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
647-V	NVzpS\|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ5IH7N	NHPPZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
HT-1376	NV:wPGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfTTWM2OD1{MTDuUS=>	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
J82	M{iyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFqzWpdKSzVyPUG4JI5O	M1O3U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
BFTC	NXfHZWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTCdYlNUUN3ME2xO{BvVQ>?	NUL3PI85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
SCaBER	NV3VO3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PPbmlEPTB;MUCgcm0>	NEfwO5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
639-V	NI\RWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHxTWM2OD1zMDDuUS=>	M3ThTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
RT112	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrtTWM2OD17IH7N	NWf2d2dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O\|g1QDN7PD;hQi=>
T24	M3rn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfpdIhPUUN3ME23JI5O	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
SW-1710	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;pbWlEPTB;NjDuUS=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N\|k9N2F-
DSH1	NF\KSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTZibl2=	MnjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N\|koRjJ2N{i0PFM6RC:jPh?=
CAL27	MmXNR5l1d3irY3n0fUBCe3OjeR?=	M4r0dlExNzVyIH7N	MViyOEBp		M1Sy[4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	MlTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEW0N\|AoRjJ3MkC1OFMxRC:jPh?=
Detroit562	MmXqR5l1d3irY3n0fUBCe3OjeR?=	M1ewVVExNzVyIH7N	NYr0VVdkOjRiaB?=		Mnvv[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEW0N\|AoRjJ3MkC1OFMxRC:jPh?=
FUDA	M2TCWGN6fG:6aXPpeJkhSXO\|YYm=	NX:1VXBTOTBxNUCgcm0>	M1TWRlI1KGh?		M3XzSIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	M1zI[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC1OFMxLz5{NUKwOVQ{ODxxYU6=
SCC25	NYrxSVFXS3m2b4jpZ4l1gSCDc4PhfS=>	MmfENVAwPTBibl2=	NFThUnAzPCCq		NXW3VJIx\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6	NILqS4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
HT-29	MnizSpVv[3Srb36gRZN{[Xl?	MYq1NI5O	NYXBVIp7OjRiaB?=	M{ezXWROW09?	NGj5SmxqdmS3Y3XkJGcxN0dzIHHydoV{fA>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzMEe5OEc,OjV{MUC3PVQ9N2F-
HCT-116	M{T5[WZ2dmO2aX;uJGF{e2G7	MVq1NI5O	MlnuNlQhcA>?	M{TUSGROW09?	MXXpcoR2[2WmIFewM2cyKGG{cnXzeC=>	MoK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVQoRjJ3MkGwO\|k1RC:jPh?=
MGC-803	MVPGeY5kfGmxbjDBd5NigQ>?	NH;yVXkxNjFvMUCwNEBvVQ>?	M{LQPFI1KGh?		M4S1PIlv\HWlZYOgS\|IwVSClZXzsMYN6[2ynIHHydoV{fA>?	NU\sUnEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
MKN-28	Mnz5R4VtdCCYaXHibYxqfHliQYPzZZk>	MYOwMlEuOTByMDDuUS=>	NUH5OGZ4PzJiaB?=		M3HiXolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M3SxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA2Lz5{NUW5NFgxPTxxYU6=
SGC-7901	MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NF\3PGExNjFvMUCwNEBvVQ>?	MWe3NkBp		MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NGL3W2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NFgxPSd-MkW1PVA5ODV:L3G+
MGC-803	NFfMc\|hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2XGfVAvOS1zMECwJI5O	NXLqZ3p2PzJiaB?=		NYTQ[IFCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NXjrR4dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
MV411	NWC0U5hqSXCxcITvd4l{KEG\|c3H5	NUPXSFdyOzBxOECvNVUxNzJ3MDDuUS=>	M1TvXVI1NzR6L{eyJIg>		NFja[FhqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM>	MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1OVAoRjJ3OEiyOVUxRC:jPh?=
HL60	MorCRZBweHSxc3nzJGF{e2G7	Mn7TN\|AwQDBxMUWwM\|I2OCCwTR?=	MmrZNlQwPDhxN{KgbC=>		M3nJb4lv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=>	M{njUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEiyOVUxLz5{NUi4NlU2ODxxYU6=
TC32	MXfxTHRUKGG\|c3H5				NGHHNYdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	MmfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MWDxTHRUKGG\|c3H5				M2C4eZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NVz4SXdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NFXMeFdyUFSVIHHzd4F6				M2XEcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NWfH[mxieUiWUzDhd5NigQ>?				MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MX7xTHRUKGG\|c3H5				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MVjxTHRUKGG\|c3H5				NFrWWXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	M2jJN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NEHPWVhyUFSVIHHzd4F6				NYTYPHJZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MmrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MYPxTHRUKGG\|c3H5				M2nFc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MYXxTHRUKGG\|c3H5				MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NH32RZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NH7hWXFyUFSVIHHzd4F6				NWPOWnNxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	M37CblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MontdWhVWyCjc4PhfS=>				MlSzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	Mkj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NFHDeWtyUFSVIHHzd4F6				M3;ZfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M4XabJFJXFNiYYPzZZk>				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NGH1dmxyUFSVIHHzd4F6				MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK ; p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4 ; Survivin / Bcl-2 / Bcl-xl / Mcl-1 ; B-RAF / C-RAF / N-RAS ; HER2 / p-STAT3 / BIM ; CDK1 / Cyclin D1 / Cyclin B1 / p27 ; c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9 ; ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3 ; Wee1 / p-Wee1 / Chk1 / p-Chk1	23418523 25077897 29717218 27834954
Growth inhibition assay	Cell viability	23418523

In vivo

Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.^[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.^[4]

Protocol (from reference)

Cell Research:^[1]

Cell lines: OSA cells
Concentrations: 0.001-1μM
Incubation Time: 5 days
Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.

Animal Research:^[4]

Animal Models: Female severe combined immune-deficient (SCID) mice
Dosages: 25 mg/kg/day for 3 days
Administration: Tail vein injection

References

[4] Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277.

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300	11mg/mL

Chemical Information

Molecular Weight	364.4
Formula	C₂₀H₂₀N₄O₃
CAS No.	888216-25-9
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

Download Ganetespib (STA-9090) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02192541	Terminated	Drug: Ziv-Aflibercept\|Drug: Ganetespib	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	December 2 2014	Phase 1
NCT02008877	Completed	Drug: ganetespib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)\|Sarcoma	Sarcoma Alliance for Research through Collaboration\|Synta Pharmaceuticals Corp.\|United States Department of Defense	December 2013	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?

Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):